40353-55-7

Basic information

• Product Name: 5-(pyridin-4-yl)thiazol-2-aMine
• Synonyms: 5-(pyridin-4-yl)thiazol-2-aMine;5-(4-PYRIDINYL)-2-THIAZOLAMINE;[5-(Pyridin-4-yl)thiazol-2-yl]amine
• CAS NO: 40353-55-7
• Molecular Formula: C₈H₇N₃S
• Molecular Weight: 177.22628
• Mol File: 40353-55-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 378.931 °C at 760 mmHg
• Flash Point: 182.971 °C
• Appearance: /
• Density: 1.333 g/cm³
• Refractive Index: 1.67
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5-(pyridin-4-yl)thiazol-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(pyridin-4-yl)thiazol-2-aMine(40353-55-7)
• EPA Substance Registry System: 5-(pyridin-4-yl)thiazol-2-aMine(40353-55-7)

Safety Data

• Hazardous Substances Data: 40353-55-7(Hazardous Substances Data)

Usage

General Description

5-(pyridin-4-yl)thiazol-2-amine is a chemical compound, often grouped under the broad category of organoheterocyclic compounds. It consists of a thiazol-2-amine group, where an amine group is replaced by a pyridine group. It is composed of an aromatic pyridine ring linked to a thiazole ring. The exact physical properties of this compound such as melting point, boiling point or density are not specifically documented, which is often the case with many complex organic compounds. It might be used in the development of pharmacological products, but more information is needed to confirm its potential applications and safety.

InChI:InChI=1/C8H7N3S/c9-8-11-5-7(12-8)6-1-3-10-4-2-6/h1-5H,(H2,9,11)

Synthetic route

4-(bromoacetyl)pyridine (6221-13-2) + thiourea (17356-08-0) → 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7)

Conditions	Yield
With triethylamine In ethanol at 60℃; for 20h;	86%
With triethylamine In ethanol at 60℃; for 20h;	86%

2,2-dimethyl-N-(5-pyridin-4-yl-thiazol-2-yl)propionamide (959986-23-3) → 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7)

Conditions	Yield
With hydrogenchloride for 4h; Reflux;
With hydrogenchloride In water for 2h; Reflux;
With hydrogenchloride In water for 2h; Reflux;

N-tert-butoxycarbonyl-L-phenylalanine (13734-34-4) + trifluoroacetic acid (76-05-1) + 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → C22H24N4O3S*C2HF3O2

Conditions	Yield
Stage #1: N-tert-butoxycarbonyl-L-phenylalanine; 5-pyridin-4-yl-thiazol-2-ylamine With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 50℃; for 6h; Stage #2: trifluoroacetic acid In water; acetonitrile for 0.75h;

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → (S)-3-phenyl-N-(5-(pyridin-4-yl)thiazol-2-yl)-2-((thiazol-5-ylmethyl)amino)propanamide trifluoroacetate

Conditions	Yield
Multi-step reaction with 3 steps 1.1: O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 6 h / 50 °C 1.2: HPLC columh / 0.75 h 2.1: trifluoroacetic acid / dichloromethane / 3 h / 20 °C 3.1: sodium tris(acetoxy)borohydride / 1,2-dichloro-ethane / 12 h / 70 °C / Inert atmosphere 3.2: HPLC columh / 0.5 h View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → C17H16N4OS

Conditions	Yield
Multi-step reaction with 2 steps 1.1: O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 6 h / 50 °C 1.2: HPLC columh / 0.75 h 2.1: trifluoroacetic acid / dichloromethane / 3 h / 20 °C View Scheme

3,4-dichlorophenylisocyanate (102-36-3) + 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → 1-(3,4-dichlorophenyl)-3-(5-(pyridin-4-yl)thiazol-2-yl)urea (1459140-13-6)

Conditions	Yield
In N,N-dimethyl-formamide at 90℃; for 1h;

4-(benzenesulfonyl)-2,6-dichloropyridine + 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → (4-benzenesulfonyl-6-chloropyridin-2-yl)-(5-pyridin-4-ylthiazol-2-yl)amine

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); sodium carbonate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In 1,4-dioxane at 120℃; for 1.5h; Inert atmosphere; Sealed tube;	70 mg

4-(benzenesulfonyl)-2,6-dichloropyridine + 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → 4-benzenesulfonyl-N-(2-methanesulfonylethyl)-N'-(5-pyridin-4-ylthiazol-2-yl)pyridine-2,6-diamine

Conditions

Yield

Multi-step reaction with 2 steps 1: sodium carbonate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; tris-(dibenzylideneacetone)dipalladium(0) / 1,4-dioxane / 1.5 h / 120 °C / Inert atmosphere; Sealed tube 2: sodium t-butanolate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; tris-(dibenzylideneacetone)dipalladium(0) / 1,2-dimethoxyethane / 24 h / 85 °C / Sealed tube View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → [6-(4-ethyl-piperazin-1-yl)-2-methyl-pyrimidin-4-yl]-(5-pyridin-4-yl-thiazol-2-yl)amine hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydride / mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C 3: hydrogenchloride / water / 0 °C View Scheme

2,4-dichloro-2-methylpyrimidine (1780-26-3) + 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → (6-chloro-2-methyl-pyrimidin-4-yl)-(5-pyridin-4-yl-thiazol-2-yl)amine

Conditions	Yield
With sodium hydride In mineral oil at 0℃; for 1h; Inert atmosphere;
With sodium hydride In 1-methyl-pyrrolidin-2-one; mineral oil at 0℃; for 1h; Inert atmosphere;

4,6-dichloropyrimidine (1193-21-1) + 5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → C12H8ClN5S

Conditions	Yield
With sodium hydride In 1-methyl-pyrrolidin-2-one; mineral oil at 0℃; for 1h; Inert atmosphere;

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → [6-(4-ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl](5-pyridin-4-yl-thiazol-2-yl)amine hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C 3: hydrogenchloride / acetone / 0 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → [6-(4-ethylpiperazin-1-yl)pyrimidin-4-yl](5-pyridin-4-yl-thiazol-2-yl)amine hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C 3: hydrogenchloride / acetone / 0 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → {6-[4-(2-fluoroethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}(5-pyridin-4-yl-thiazol-2-yl)amine hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C 3: hydrogenchloride / acetone / 0 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → 2-{4-[2-methyl-6-(5-pyridin-4-ylthiazol-2-ylamino)pyrimidin-4-yl]piperazin-1-yl}ethanol hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C 3: hydrogenchloride / acetone / 0 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → [6-(4-dimethylaminopiperidin-1-yl)-2-methylpyrimidin-4-yl](5-pyridin-4-yl-thiazol-2-yl)amine hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C 3: hydrogenchloride / acetone / 0 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → [2-methyl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl](5-pyridin-4-yl-thiazol-2-yl)amine hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: potassium hydroxide / diethylene glycol dimethyl ether / 0.17 h / 100 - 160 °C / Inert atmosphere 3: hydrogenchloride / methanol / 0 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → [6-(4-ethyl-piperazin-1-yl)-2-methyl-pyrimidin-4-yl]-(5-pyridin-4-yl-thiazol-2-yl)amine

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → C18H21N7S

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → {6-[4-(2-fluoro-ethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl}-(5-pyridin-4-yl-thiazol-2-yl)amine

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → 2-{4-[2-methyl-6-(5-pyridin-4-yl-thiazol-2-ylamino)pyrimidin-4-yl]piperazin-1-yl}ethanol

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → [6-(4-dimethylamino-piperidin-1-yl)-2-methyl-pyrimidin-4-yl]-(5-pyridin-4-yl-thiazol-2-yl)amine

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: dimethyl sulfoxide / 1 h / 100 °C View Scheme

5-pyridin-4-yl-thiazol-2-ylamine (40353-55-7) → C19H22N6O2S

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydride / 1-methyl-pyrrolidin-2-one; mineral oil / 1 h / 0 °C / Inert atmosphere 2: potassium hydroxide / diethylene glycol dimethyl ether / 0.17 h / 100 - 160 °C / Inert atmosphere View Scheme

Upstream product

• 959986-23-3 2,2-dimethyl-N-(5-pyridin-4-yl-thiazol-2-yl)propionamide 
• 6221-13-2 4-(bromoacetyl)pyridine 
• 17356-08-0 thiourea 

Downstream Products

• 1459140-13-6 1-(3,4-dichlorophenyl)-3-(5-(pyridin-4-yl)thiazol-2-yl)urea 

Relevant articles and documents

Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Gastrointestinal stromal tumors (GISTs) are prototypes of stem cell factor receptor (c-KIT)-driven cancer. Two receptor tyrosine kinases, c-KIT and fms-tyrosine kinase (FLT3), are frequently mutated in acute myeloid leukemia (AML) patients, and these mutations are associated with poor prognosis. In this study, we discovered a multitargeted tyrosine kinase inhibitor, compound 15a, with potent inhibition against single or double mutations of c-KIT developed in GISTs. Moreover, crystal structure analysis revealed the unique binding mode of 15a with c-KIT and may elucidate its high potency in inhibiting c-KIT kinase activity. Compound 15a inhibited cell proliferation and induced apoptosis by targeting c-KIT in c-KIT-mutant GIST cell lines. The antitumor effects of 15a were also demonstrated in GIST430 and GIST patient-derived xenograft models. Further studies demonstrated that 15a inhibited the proliferation of c-KIT- and FLT3-driven AML cells in vitro and in vivo. The results of this study suggest that 15a may be a potential anticancer drug for the treatment of GISTs and AML.

SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Provided are sulfonylaminopyridine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where n, R1, R2, R3, R6 and R7 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by ITK kinase in a patient.

PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS

Provided herein are compounds of formula I: wherein A, B, X, R1 , R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions